Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.

Monika KoziełMichał MazurekChristine TeutschHans-Christoph DienerSergio J DubnerJonathan L HalperinChang-Sheng MaKenneth J RothmanAxel BrandesMiney PaquetteKristina ZintLionel Riou FrançaShihai LuDorothee B BartelsMenno V Huisman Gregory Yoke Hong Lip

Published in: Journal of clinical medicine (2020)

Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

Keyphrases

atrial fibrillation
oral anticoagulants
phase iii
clinical trial
open label
left atrial
catheter ablation
heart failure
left atrial appendage
venous thromboembolism
emergency department
percutaneous coronary intervention
randomized controlled trial
double blind
coronary artery disease
mitral valve
adverse drug